from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A monoclonal antibody which is linked with yttrium-90 as the drug ibritumomab tiuxetan


Sorry, no etymologies found.


  • The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.

    Yahoo! News: Business - Opinion

  • ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.


  • Data from clinical trials suggest that radio-immunotherapy (RIT) consolidation therapy is an important treatment approach for patients with follicular lympho ma (FL), with striking phase 3 results recently published for 90Y-ibritumomab tiuxetan Home Page

  • -- (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Featured News and Stories

  • ZEVALIN (ibritumomab tiuxetan) is a CD20-directed radiotherapeutic antibody administered as part of the ZEVALIN therapeutic regimen. Featured News and Stories

  • Zevalin® (Yttrium-90 [(90) Y] ibritumomab tiuxetan) appears to provide effective, long-term anticancer responses for patients with follicular lymphoma whose cancer has progressed following an autologous stem cell transplant.


  • Zevalin® (Yttrium-90 [(90) Y] ibritumomab tiuxetan) appears highly effective in the treatment of primary cutaneous B-cell lymphoma (PCBCL).


  • Administration of Zevalin® (Y-ibritumomab tiuxetan) immediately following initial chemotherapy for advanced follicular lymphoma improves progression-free survival for two years compared with chemotherapy alone.


  • Following radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma


  • (ibritumomab tiuxetan) in the first-line consolidation setting for non-Hodgkin's Lymphoma

    Healthcare Sector and Stocks Analysis from Seeking Alpha


Log in or sign up to get involved in the conversation. It's quick and easy.